Effect of Sofosbuvir-daclatasuvir on Angiogenesis

Sherief Abd-Elsalam

Status: Enrolling

Conditions: HCV Coinfection

Treatments: Drug: Sofosbuvir-daclatasvir

Study type: Interventional

Funder types: Other

Identifiers

NCT03646396

sofosbuvir angiogenesis

Details and patient eligibility

About

The study aimed at study of the Effect of Daclatasvir Plus Sofosbuvir on Angiogenesis in Egyptian Patients With Chronic HCV Infection

Full description

The study primary aim was at evaluation of the Effect of Daclatasvir Plus Sofosbuvir on Angiogenesis in Egyptian Patients With Chronic HCV Infection

Enrollment: 40 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Chronic HCV patients

Exclusion criteria

• HCC.
• HIV or HBV.
• Malignancy.
• Pregnancy.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

40 participants in 1 patient group

Sofosbuvir-daclatasvir

Experimental group

Description:

Sofosbuvir-daclatasvir for 3 months

Treatment:

Drug: Sofosbuvir-daclatasvir